XTX Topco Ltd Makes New $362,000 Investment in Qiagen (NYSE:QGEN)

XTX Topco Ltd purchased a new stake in Qiagen (NYSE:QGEN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,807 shares of the company’s stock, valued at approximately $362,000.

Several other hedge funds have also recently modified their holdings of QGEN. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Qiagen by 24.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 23,751 shares of the company’s stock worth $958,000 after purchasing an additional 4,608 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Qiagen by 57.0% during the second quarter. Mercer Global Advisors Inc. ADV now owns 9,723 shares of the company’s stock valued at $400,000 after buying an additional 3,530 shares during the last quarter. Redwood Wealth Management Group LLC bought a new stake in shares of Qiagen in the 2nd quarter valued at about $139,000. Envestnet Asset Management Inc. grew its position in shares of Qiagen by 3.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 351,372 shares of the company’s stock worth $14,452,000 after buying an additional 11,392 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock worth $133,292,000 after acquiring an additional 353,280 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on QGEN. Robert W. Baird lifted their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Finally, Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Thursday, June 27th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.10.

Qiagen Stock Up 2.1 %

Qiagen stock opened at $45.02 on Friday. The business’s 50-day simple moving average is $45.13 and its two-hundred day simple moving average is $43.49. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The company has a market cap of $10.27 billion, a PE ratio of 30.19, a PEG ratio of 3.17 and a beta of 0.39. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.44.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. During the same quarter in the prior year, the firm earned $0.53 earnings per share. Qiagen’s revenue for the quarter was down .2% on a year-over-year basis. Equities analysts anticipate that Qiagen will post 2.15 EPS for the current year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.